Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.74%||178.19||0.7%||$1350.94m|
|MRK||Merck & Co., Inc.||0.21%||92.61||0.7%||$1211.55m|
|LLY||Eli Lilly & Co.||0.74%||327.13||1.1%||$1026.00m|
|BMY||Bristol-Myers Squibb Co.||-1.13%||75.97||1.0%||$991.64m|
|TPTX||Turning Point Therapeutics, Inc.||0.05%||75.15||0.0%||$199.28m|
|HZNP||Horizon Therapeutics Plc||2.38%||82.76||5.4%||$174.09m|
|MRTX||Mirati Therapeutics, Inc.||1.10%||71.96||1.6%||$150.81m|
|ALNY||Alnylam Pharmaceuticals, Inc.||1.67%||150.73||8.1%||$150.31m|
|NVO||Novo Nordisk A/S||-0.40%||111.19||0.1%||$148.30m|
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.